AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06061276
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Trial: NCT06061276
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenously every 2 weeks
Trial: NCT05497102
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
Trial: NCT05452369
Drug: Rhomboid intercostal plane block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
Trial: NCT00236990
Drug: pentosan polysulfate sodium
RxNorm normalized name: Pentosan Polysulfate Sodium
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06009237
Drug: ABBV-903
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; oral
Trial: NCT05347225
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemtabrutinib tablets will be administered orally QD.
Trial: NCT06307522
Drug: MRG-001
RxNorm normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive subcutaneous administration of MRG-001 at designated visits.
Trial: NCT05852158
Drug: Cefazolin 2 GM Injection
RxNorm normalized name: ceFAZolin 2 GM Injection
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pre-op dose of 2g IV cefazolin
Trial: NCT05852158
Drug: Cefazolin Injection
RxNorm normalized name: cefazolin Injection
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
Trial: NCT06606561
Drug: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
Trial: NCT06606561
Drug: 0.9% Sodium Chloride Injection, USP
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
Trial: NCT05032690
Drug: Bosutinib capsule
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
Trial: NCT05032690
Drug: Bosutinib capsule
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
Trial: NCT05032690
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
Trial: NCT05032690
Drug: Bosutinib capsule
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
Trial: NCT06607419
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
Trial: NCT05893771
Drug: Methylprednisolone Injection
RxNorm normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
Trial: NCT05893771
Drug: Bupivacaine Hcl 0.5% Inj_#2
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
Trial: NCT05370963
Drug: Hylase versus dexmedtemodine
RxNorm normalized name: Hylase Wound
DrugBank: Emodin (DB07715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluroscopic guided lumber epidural injection
Trial: NCT05098938
Drug: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (upper gum area), 50mg, 1 tablet.
Trial: NCT04726033
Drug: 64Cu-DOTA-TLX592
RxNorm normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
Trial: NCT06301828
Drug: Envafolimab Injection
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar+SBRT+Envafolimab Injection
Trial: NCT06301828
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar+SBRT+Envafolimab Injection
Trial: NCT04488159
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusion
Trial: NCT05346146
Drug: Sintilimab; Gemcitabine; Albumin-paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
Trial: NCT06454448
Drug: Adebrelimab;decitabine;
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
Trial: NCT05651789
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
Trial: NCT05113186
Drug: Lenvatinib Pill
RxNorm normalized name: lenvatinib Pill
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)
Trial: NCT05651789
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
Trial: NCT05133830
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: OCA will be administered
Trial: NCT05133830
Drug: Linerixibat
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linerixibat will be administered
Trial: NCT05515588
Drug: BI 690517 (C-14)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517 (C-14)
Trial: NCT05515588
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517
Trial: NCT05056220
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
Trial: NCT05056220
Drug: sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
Trial: NCT06339242
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
Trial: NCT06505941
Drug: umbilical cord mesenchymal stem cell
RxNorm normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umbilical cord mesenchymal stem cell
Trial: NCT06475209
Drug: Adebrelimab combined with Apatinib
RxNorm normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
Trial: NCT06012500
Drug: Xenon-129
RxNorm normalized name: xenon-129
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled contrast for MRI
Trial: NCT05688215
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05688215
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05688215
Drug: Quemliclustat
RxNorm normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT05688215
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05465798
Drug: MC 3x3
RxNorm normalized name: MC-3
DrugBank: TMC-310911 (DB15623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
Trial: NCT06439433
Drug: Aminolaevulinic acid (500-mg bottle)
DrugBank: Laevulinic Acid (DB02239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a week for 6 weeks
Trial: NCT06439433
Drug: Aminolaevulinic acid (750-mg bottle)
DrugBank: Laevulinic Acid (DB02239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a week for 6 weeks
Trial: NCT03294174
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine administered to provide nerve block
Trial: NCT06214130
Drug: Sodium valproate 500 MG
RxNorm normalized name: Sodium valproate 500 mg gastro-resistant oral tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral intake
Trial: NCT06214130
Drug: Valproic Acid 500 MG
RxNorm normalized name: valproic acid 500 MG
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral intake
Trial: NCT05791409
Drug: Epcoritamab
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
Trial: NCT05791409
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
Trial: NCT05247970
Drug: S-309309
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule administered orally
Trial: NCT05247970
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Syrup administered orally
Trial: NCT05377658
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
Trial: NCT05377658
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
Trial: NCT05377658
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
Trial: NCT06174688
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular Injections
Trial: NCT04992065
Drug: Evolocumab 140 mg/mL, Repatha®
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL
Trial: NCT06504186
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.
Trial: NCT06241638
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Trial: NCT05494307
Drug: Terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
Trial: NCT05494307
Drug: Danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally danazol at a dose of 200 mg twice daily for 16 weeks
Trial: NCT06210542
Drug: ceftazidime avibactam
RxNorm normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL
Trial: NCT06233201
Drug: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
Trial: NCT06233201
Drug: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
Trial: NCT05723432
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab will be administered intravenously.
Trial: NCT05426031
Drug: Protamine fixed dose
RxNorm normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg of protamine intravenously (IV), one time use
Trial: NCT05426031
Drug: Protamine ratio dose
RxNorm normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg of protamine per 100 units of heparin given intravenously (IV), one time use
Trial: NCT04809818
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading and maintenance doses of Aspirin administered by oral
Trial: NCT04809818
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Loading and maintenance doses of Clopidogrel administered by oral
Trial: NCT04809818
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multiple doses of Apixaban administered by oral
Trial: NCT04809818
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Dabigatran administered by oral
Trial: NCT06193408
Drug: VR-AD-1005
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT04720716
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab IV d1, Q3W
Trial: NCT04720716
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg po
Trial: NCT06488482
Drug: nivolumab or pembrolizumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: See above
Trial: NCT04430933
Drug: NC318
RxNorm normalized name: Nivolumab and Relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
Trial: NCT04430933
Drug: Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Trial: NCT04430933
Drug: Nab paclitaxel/Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
Trial: NCT04430933
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
Trial: NCT06281665
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
Trial: NCT02650271
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be received entecavir (10 mg/d) before liver resection.
Trial: NCT02650271
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be received tenofovir before liver resection.
Trial: NCT04774536
Drug: CRISPR_SCD001
RxNorm normalized name: Mentha crispa oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.